Announcements Trials
Browse Landscape

Phase

Phase 2 28Phase 1 20Phase 1/2 11Phase 3 8Phase NA 5Phase 4 3Phase 2/3 3Phase EARLY_PHASE1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 53Classical hematology 21Genitourinary 14Gastrointestinal 13Breast 9Other hematologic neoplasm 8Thoracic 5Other 5Plasma cell 4Lymphoid 4Gynecologic 4Dermatologic 4CNS 4Sarcoma 3NET 3Endocrine 3Myeloid 2Head & Neck 2

Conditions

Pituitary Neoplasms 15Neuroendocrine Tumors 15Multiple Endocrine Neoplasia Type 1 9Inflammation 4Acromegaly 4Sexual Dysfunction, Physiological 3Pheochromocytoma 3Obesity 3Neoplasms 3Gastro-enteropancreatic neuroendocrine tumor 3Thyroid Cancer, Papillary 2Prostatic Neoplasms 2Pituitary Diseases 2Paraganglioma 2Carcinoid Tumor 2Adrenal Gland Neoplasms 2Zollinger-Ellison Syndrome 1Vitamin D Deficiency 1Serotonin Syndrome 1Pituitary ACTH Hypersecretion 1Pancreatic Neuroendocrine Tumors 1Pancreatic Neoplasms 1Pain, Postoperative 1Pain 1Neuroendocrine Tumour With Carcinoid Symptoms 1Multiple Endocrine Neoplasia 1Meningioma 1Melanoma 1Medulloblastoma 1Lung Neoplasms 1

Interventions

pasireotide 1Sunitinib 1Octreotide 1Everolimus 1Cabergoline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × Neoplasms × Endocrine × Clear all
NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

NCT01789281 2021-06-11

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

Novartis

Phase 4 Completed
34 enrolled 8 charts
EndocrineNET

Carcinoid Tumor, Neoplasms, Neuroendocrine Tumors

NCT01525550 2019-07-30

A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Pfizer

Phase 4 Completed
106 enrolled 26 charts
EndocrineGastrointestinalNET

Adenoma, Carcinoma, Neoplasms, Pancreatic Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡